Biotech startups in Los Angeles

Christopher Anzalone (CEO)

Publicly traded (NASDAQ: ARWR) RNAi therapeutics company developing TRiM-platform siRNA drugs that silence disease-causing genes across cardiometabolic, pulmonary and rare diseases. In 2024 it signed a licen...

Patrick Soon-Shiong (Founder/Exec Chairman)

Public (NASDAQ: IBRX) immunotherapy company founded 2014 by billionaire physician-scientist Patrick Soon-Shiong. Won FDA approval of ANKTIVA (N-803) for BCG-unresponsive bladder cancer in 2024 — a milestone ...

Alan Auerbach (Founder/CEO)

Public (NASDAQ: PBYI) commercial-stage oncology biopharma headquartered on the Wilshire Corridor. Markets NERLYNX (neratinib) for HER2-positive breast cancer and is advancing alisertib (aurora kinase inhibit...

Bassil Dahiyat (Co-founder/CEO)

Public (NASDAQ: XNCR) antibody- and cytokine-engineering biotech built on the proprietary XmAb bispecific platform, spun from Caltech-linked protein-design science. Pipeline spans oncology and autoimmune (e....

Lili Yang, Gay Crooks, David Baltimore (UCLA/Caltech founders)

UCLA spinout (founded 2020) developing 'off-the-shelf' allogeneic CAR-iNKT and stem-cell-derived cell therapies via its ACUA and EngIL platforms. Raised a $52M Series A (Two River/8VC) and partnered with Kit...

Daniel Gil, William Lowry, Heather Christofk (UCLA)

UCLA-spinout biotech targeting hair-follicle regeneration by reactivating stem cells via metabolic (lactate/MPC) pathways. Raised a $16.75M Series A led by GV (Google Ventures) in 2024 and reported positive ...

Ken Schultz, Caius Radu (UCLA founders)

Clinical-stage biotech commercializing UCLA nucleotide-metabolism science; lead drug TRE-515 is a first-in-class oral deoxycytidine-kinase (dCK) inhibitor. Won FDA Fast Track in metastatic prostate cancer an...